Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis

• Status: Completed
• Trial end date: 2020-01-31
• Target enrollment: 0
• Participant gender: All

Summary

The study is aimed at evaluating the efficacy and safety of anticoagulant therapy with nadroparin calcium and warfarin in patients with portal vein thrombosis (PVT).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Qilu Hospital of Shandong University
• Treatments: Anticoagulants; Calcium; Calcium heparin; Dalteparin; Heparin; Heparin, Low-Molecular-Weight; Nadroparin; Warfarin

Criteria

Inclusion Criteria:

• Age between 18 and 75 years

• Liver cirrhosis diagnosis based on clinical, laboratory, and imaging studies, and PVT diagnosed by abdominal contrast-enhanced computed tomography, contrast-enhanced MRI, or portal angiography

Exclusion Criteria:

• Cavernous transformation of the portal vein

• Uncontrolled active bleeding

• Platelet count lower than 10*10^9/L

• Creatinine more than 170 mmol/L

• Ongoing or received antithrombotic/thrombolytic treatment

• Primary thrombophilia

• Budd-Chiari syndrome

• Pregnancy or breast-feeding period

• Severe cardiopulmonary diseases

• Severe systemic infection or sepsis

• Inability to sign informed consent